ABVC BioPharma (ABVC BioPharma) COGS-to-Revenue : 69.50 (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is ABVC BioPharma COGS-to-Revenue?

ABVC BioPharma's Cost of Goods Sold for the three months ended in Dec. 2023 was $0.14 Mil. Its Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

ABVC BioPharma's COGS to Revenue for the three months ended in Dec. 2023 was 69.50.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. ABVC BioPharma's Gross Margin % for the three months ended in Dec. 2023 was -6,850.00%.

ABVC BioPharma COGS-to-Revenue Historical Data

The historical data trend for ABVC BioPharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ABVC BioPharma COGS-to-Revenue Chart

ABVC BioPharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

Get a 7-Day Free Trial

0.03

0.04

0.01

0.30

1.99

ABVC BioPharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue	Get a 7-Day Free Trial															0.45	0.47	12.17	1.88	69.50

ABVC BioPharma COGS-to-Revenue Calculation

ABVC BioPharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.302	/	0.152
	=	1.99

ABVC BioPharma's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.139	/	0.002
	=	69.50

ABVC BioPharma (NAS:ABVC) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

ABVC BioPharma's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.139 / 0.002
	=	-6,850.00 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

ABVC BioPharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of ABVC BioPharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

ABVC BioPharma (ABVC BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ABVC BioPharma Inc (NAS:ABVC) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

44370 Old Warm Springs Boulevard, Fremont, CA, USA, 94538

Website

https://www.abvcpharma.com

ABVC BioPharma Inc is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. For its drug products, it is focused on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm is specialized in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.

Executives

Shuling Jiang	director, 10 percent owner	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Shih-chen Tseng	director	5F., NO. 41-1, LN. 12, SINDONG ST., SONGSHAN DIST, TAIPEI CITY F5 105065
Yoshinobu Odaira	director	4823 DUNDAS STREET, THOMDALE, LONDON X0 N6P 1J1
Norimi Sakamoto	director	4823 DUNDAS STREET, THRONDALE, LONDON X0 N6P 1J1
Shin-yu Miao	director	NO. 25-12, AMLIN RD., XITUN DIST., TAICHUNG CITY F5 407676
Tsung Shann Jiang	director, officer: CSO and Director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Eugene Jiang	director, officer: Chairman of the Board & CBO	1197 LA PLURISSIMA PL, FREMONT CA 94539
Chang-jen Jiang	director	1197 LA PLURISSIMA PL, FREMONT CA 94539
Yen-hsin Chou	director	13F. NO. 2, MEISHU E. 8TH ST.,, GUSHAN DIST., KAOHSIUNG CITY F5 804413
Chi-hsin Richard King	officer: Chief Scientific Officer	11907 GRANT PLACE, SAINT LOUIS MO 63131
Howard Doong	officer: Chief Executive Officer	44370 OLD WARM SPRINGS BLVD., FREMONT CA 94538
Chihliang An	officer: Chief Financial Officer	32458 JEAN DR, UNION CITY CA 94587
Tsang Ming Jiang	director	1197 LA PURISSIMA PL, FREMONT CA 94539
Shulamit Lazar	director, 10 percent owner, officer: President,Secretary,Treasurer	8605 SANTA MONICA BOULEVARD, SUITE 41336, LOS ANGELES CA 90069
Kevin Patrick Stolz	officer: CFO & Controller	2701 CAMBRIDGE COURT, SUITE 100, AUBURN HILLS MI 48326